

# Janine Reichenbach

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6706092/publications.pdf>

Version: 2024-02-01

87  
papers

8,686  
citations

66343

42  
h-index

56724

83  
g-index

88  
all docs

88  
docs citations

88  
times ranked

11429  
citing authors

#	ARTICLE	IF	CITATIONS
1	Catapult-like release of mitochondrial DNA by eosinophils contributes to antibacterial defense. <i>Nature Medicine</i> , 2008, 14, 949-953.	30.7	836
2	Gain-of-function human <i>STAT1</i> mutations impair IL-17 immunity and underlie chronic mucocutaneous candidiasis. <i>Journal of Experimental Medicine</i> , 2011, 208, 1635-1648.	8.5	739
3	Restoration of NET formation by gene therapy in CGD controls aspergillosis. <i>Blood</i> , 2009, 114, 2619-2622.	1.4	500
4	Heterozygous <i>STAT1</i> gain-of-function mutations underlie an unexpectedly broad clinical phenotype. <i>Blood</i> , 2016, 127, 3154-3164.	1.4	465
5	Mutations in <i>STAT3</i> and <i>IL12RB1</i> impair the development of human IL-17-producing T cells. <i>Journal of Experimental Medicine</i> , 2008, 205, 1543-1550.	8.5	406
6	Revisiting Human IL-12R $\beta$ 1 Deficiency. <i>Medicine (United States)</i> , 2010, 89, 381-402.	1.0	367
7	Clinical Features and Outcome of Patients With IRAK-4 and MyD88 Deficiency. <i>Medicine (United States)</i> , 2010, 89, 403-425.	1.0	366
8	A hypermorphic <i>IL12RB1</i> mutation is associated with autosomal dominant anhidrotic ectodermal dysplasia and T cell immunodeficiency. <i>Journal of Clinical Investigation</i> , 2003, 112, 1108-1115.	8.2	325
9	The transmembrane activator TACI triggers immunoglobulin class switching by activating B cells through the adaptor MyD88. <i>Nature Immunology</i> , 2010, 11, 836-845.	14.5	295
10	Novel signal transducer and activator of transcription 3 (STAT3) mutations, reduced TH17 cell numbers, and variably defective STAT3 phosphorylation in hyper-IgE syndrome. <i>Journal of Allergy and Clinical Immunology</i> , 2008, 122, 181-187.	2.9	290
11	Inflammasome activation in NADPH oxidase defective mononuclear phagocytes from patients with chronic granulomatous disease. <i>Blood</i> , 2010, 116, 1570-1573.	1.4	249
12	Restoration of anti-Aspergillus defense by neutrophil extracellular traps in human chronic granulomatous disease after gene therapy is calprotectin-dependent. <i>Journal of Allergy and Clinical Immunology</i> , 2011, 127, 1243-1252.e7.	2.9	221
13	Loss of B Cells in Patients with Heterozygous Mutations in IKAROS. <i>New England Journal of Medicine</i> , 2016, 374, 1032-1043.	27.0	217
14	Clinical and immunologic phenotype associated with activated phosphoinositide 3-kinase $\gamma$ syndrome 2: A cohort study. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 138, 210-218.e9.	2.9	215
15	Autophagy proteins stabilize pathogen-containing phagosomes for prolonged MHC II antigen processing. <i>Journal of Cell Biology</i> , 2013, 203, 757-766.	5.2	172
16	Interleukin-12 Receptor $\beta$ 1 Deficiency in a Patient with Abdominal Tuberculosis. <i>Journal of Infectious Diseases</i> , 2001, 184, 231-236.	4.0	159
17	Elevated Oxidative Stress in Patients with Ataxia Telangiectasia. <i>Antioxidants and Redox Signaling</i> , 2002, 4, 465-469.	5.4	152
18	Gene Therapy of Chronic Granulomatous Disease: The Engraftment Dilemma. <i>Molecular Therapy</i> , 2011, 19, 28-35.	8.2	147

#	ARTICLE	IF	CITATIONS
19	Diagnostic approach to the hyper-IgE syndromes: Immunologic and clinical key findings to differentiate hyper-IgE syndromes from atopic dermatitis. <i>Journal of Allergy and Clinical Immunology</i> , 2010, 126, 611-617.e1.	2.9	140
20	Disease Evolution and Response to Rapamycin in Activated Phosphoinositide 3-Kinase Î Syndrome: The European Society for Immunodeficiencies-Activated Phosphoinositide 3-Kinase Î Syndrome Registry. <i>Frontiers in Immunology</i> , 2018, 9, 543.	4.8	137
21	Bacillus Calmette GuÃ©rin triggers the IL-12/IFN-Î³ axis by an IRAK-4- and NEMO-dependent, non-cognate interaction between monocytes, NK, and Tâ€¸ lymphocytes. <i>European Journal of Immunology</i> , 2004, 34, 3276-3284.	2.9	133
22	Nuclear factor Î² essential modulatorâ€™ deficient child with immunodeficiency yet without anhidrotic ectodermal dysplasia. <i>Journal of Allergy and Clinical Immunology</i> , 2004, 114, 1456-1462.	2.9	122
23	Identification of Severe Combined Immunodeficiency by T-Cell Receptor Excision Circles Quantification Using Neonatal Guthrie Cards. <i>Journal of Pediatrics</i> , 2009, 155, 829-833.	1.8	108
24	Impaired Interferon Gamma-Mediated Immunity and Susceptibility to Mycobacterial Infection in Childhood. <i>Pediatric Research</i> , 2001, 50, 8-13.	2.3	97
25	Mycobacterial diseases in primary immunodeficiencies. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2001, 1, 503-511.	2.3	94
26	Quantification of Î²-deleting recombination excision circles in Guthrie cards for the identification of early B-cell maturation defects. <i>Journal of Allergy and Clinical Immunology</i> , 2011, 128, 223-225.e2.	2.9	91
27	The NEMO Mutation Creating the Most-Upstream Premature Stop Codon Is Hypomorphic Because of a Reinitiation of Translation. <i>American Journal of Human Genetics</i> , 2006, 78, 691-701.	6.2	89
28	TALEN-mediated functional correction of X-linked chronic granulomatous disease in patient-derived induced pluripotent stem cells. <i>Biomaterials</i> , 2015, 69, 191-200.	11.4	76
29	Actinomyces in Chronic Granulomatous Disease: An Emerging and Unanticipated Pathogen. <i>Clinical Infectious Diseases</i> , 2009, 49, 1703-1710.	5.8	74
30	Hyperinflammation in patients with chronic granulomatous disease leads to impairment of hematopoietic stem cell functions. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 138, 219-228.e9.	2.9	74
31	Immunogenicity and Tolerance of a 7-Valent Pneumococcal Conjugate Vaccine in Nonresponders to the 23-Valent Pneumococcal Vaccine. <i>Infection and Immunity</i> , 2000, 68, 1435-1440.	2.2	72
32	Derivation and Functional Analysis of Patient-Specific Induced Pluripotent Stem Cells as an In Vitro Model of Chronic Granulomatous Disease. <i>Stem Cells</i> , 2012, 30, 599-611.	3.2	69
33	NEMO is a key component of NF-Î²Bâ€™ and IRF-3â€™ dependent TLR3-mediated immunity to herpes simplex virus. <i>Journal of Allergy and Clinical Immunology</i> , 2011, 128, 610-617.e4.	2.9	66
34	Immunoglobulin Deficiencies: The B-Lymphocyte Side of DiGeorge Syndrome. <i>Journal of Pediatrics</i> , 2012, 161, 950-953.e1.	1.8	63
35	Ikaros family zinc finger 1 regulates dendritic cell development and function in humans. <i>Nature Communications</i> , 2018, 9, 1239.	12.8	62
36	Successful Combination of Sequential Gene Therapy and Rescue Allo-HSCT in Two Children with X-CGD - Importance of Timing. <i>Current Gene Therapy</i> , 2015, 15, 416-427.	2.0	61

#	ARTICLE	IF	CITATIONS
37	Neutrophil oxidative burst activates ATM to regulate cytokine production and apoptosis. <i>Blood</i> , 2015, 126, 2842-2851.	1.4	58
38	From idiopathic infectious diseases to novel primary immunodeficiencies. <i>Journal of Allergy and Clinical Immunology</i> , 2005, 116, 426-430.	2.9	57
39	Severe glucose-6-phosphate dehydrogenase deficiency leads to susceptibility to infection and absent NETosis. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 139, 212-219.e3.	2.9	56
40	Deficiencies in CD4+ and CD8+ T cell subsets in ataxia telangiectasia. <i>Clinical and Experimental Immunology</i> , 2002, 129, 125-132.	2.6	54
41	Growth factor deficiency in patients with ataxia telangiectasia. <i>Clinical and Experimental Immunology</i> , 2005, 140, 517-519.	2.6	50
42	Clinical, molecular, and cellular immunologic findings in patients with SP110-associated veno-occlusive disease with immunodeficiency syndrome. <i>Journal of Allergy and Clinical Immunology</i> , 2012, 130, 735-742.e6.	2.9	49
43	The Swiss National Registry for Primary Immunodeficiencies: report on the first 6 yearsâ€™ activity from 2008 to 2014. <i>Clinical and Experimental Immunology</i> , 2015, 182, 45-50.	2.6	46
44	The European Society for Immunodeficiencies (ESID) registry 2014. <i>Clinical and Experimental Immunology</i> , 2014, 178, 18-20.	2.6	43
45	Heterozygous signal transducer and activator of transcription 3 mutations in hyper-IgE syndrome result in altered B-cell maturation. <i>Journal of Allergy and Clinical Immunology</i> , 2012, 129, 559-562.e2.	2.9	41
46	Extracerebellar MRIâ€™Lesions in Ataxia Telangiectasia Go Along with Deficiency of the GH/IGF-1 Axis, Markedly Reduced Body Weight, High Ataxia Scores and Advanced Age. <i>Cerebellum</i> , 2010, 9, 190-197.	2.5	35
47	Human DOCK2 Deficiency: Report of a Novel Mutation and Evidence for Neutrophil Dysfunction. <i>Journal of Clinical Immunology</i> , 2019, 39, 298-308.	3.8	31
48	Fatal Neonatal-Onset Mitochondrial Respiratory Chain Disease with T Cell Immunodeficiency. <i>Pediatric Research</i> , 2006, 60, 321-326.	2.3	30
49	IMMUNOGENICITY OF THE SEVEN VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PATIENTS WITH ATAXIA-TELANGIECTASIA. <i>Pediatric Infectious Disease Journal</i> , 2004, 23, 269-270.	2.0	29
50	First Successful Bone Marrow Transplantation for X-linked Chronic Granulomatous Disease by Using Preimplantation Female Gender Typing and HLA Matching. <i>Pediatrics</i> , 2008, 122, e778-e782.	2.1	26
51	Modern management of primary Bâ€™cell immunodeficiencies. <i>Pediatric Allergy and Immunology</i> , 2011, 22, 758-769.	2.6	23
52	Gene Therapy for Chronic Granulomatous Disease: Current Status and Future Perspectives. <i>Current Gene Therapy</i> , 2014, 14, 447-460.	2.0	21
53	Autosomal-dominant primary immunodeficiencies. <i>Current Opinion in Hematology</i> , 2005, 12, 22-30.	2.5	20
54	Intact indoleamine 2,3-dioxygenase activity in human chronic granulomatous disease. <i>Clinical Immunology</i> , 2010, 137, 1-4.	3.2	19

#	ARTICLE	IF	CITATIONS
55	Human miR223 Promoter as a Novel Myelo-Specific Promoter for Chronic Granulomatous Disease Gene Therapy. <i>Human Gene Therapy Methods</i> , 2013, 24, 151-159.	2.1	18
56	Non-invasive near-infrared fluorescence imaging of the neutrophil response in a mouse model of transient cerebral ischaemia. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2017, 37, 2833-2847.	4.3	18
57	Swiss newborn screening for severe T and B cell deficiency with a combined TREC/KREC assay – management recommendations. <i>Swiss Medical Weekly</i> , 2020, 150, w20254.	1.6	17
58	Persistent mammalian orthoreovirus, coxsackievirus and adenovirus co-infection in a child with a primary immunodeficiency detected by metagenomic sequencing: a case report. <i>BMC Infectious Diseases</i> , 2018, 18, 33.	2.9	16
59	CRISPR/Cas9-generated p47phox-deficient cell line for Chronic Granulomatous Disease gene therapy vector development. <i>Scientific Reports</i> , 2017, 7, 44187.	3.3	15
60	High Levels of IL-18 and IFN- $\gamma$ in Chronically Inflamed Tissue in Chronic Granulomatous Disease. <i>Frontiers in Immunology</i> , 2019, 10, 2236.	4.8	15
61	Impaired interferon- $\gamma$ production in response to live bacteria and Toll-like receptor agonists in patients with ataxia telangiectasia. <i>Clinical and Experimental Immunology</i> , 2006, 146, 381-389.	2.6	14
62	Defective nuclear entry of hydrolases prevents neutrophil extracellular trap formation in patients with chronic granulomatous disease. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 136, 1703-1706.e5.	2.9	14
63	Spontaneous and oxidative stress-induced programmed cell death in lymphocytes from patients with ataxia telangiectasia (AT). <i>Clinical and Experimental Immunology</i> , 2000, 119, 140-147.	2.6	13
64	Increased number of activated T cells in lymphocyte subsets of maltreated children: Data from a pilot study. <i>Journal of Psychosomatic Research</i> , 2012, 73, 313-318.	2.6	12
65	Safety and Tolerability of Methacholine Challenge in Infants with Recurrent Wheeze. <i>Journal of Asthma</i> , 2003, 40, 795-802.	1.7	9
66	Modern management of phagocyte defects. <i>Pediatric Allergy and Immunology</i> , 2017, 28, 124-134.	2.6	9
67	Severe adenovirus bronchiolitis in children. <i>Acta Paediatrica, International Journal of Paediatrics</i> , 2000, 89, 1387-1389.	1.5	9
68	CRISPR-Directed Therapeutic Correction at the NCF1 Locus Is Challenged by Frequent Incidence of Chromosomal Deletions. <i>Molecular Therapy - Methods and Clinical Development</i> , 2020, 17, 936-943.	4.1	8
69	Effectiveness of budesonide nebulising suspension compared to disodium cromoglycate in early childhood asthma. <i>Current Medical Research and Opinion</i> , 2006, 22, 367-373.	1.9	7
70	Immunoglobulins and Inflammatory Cytokines in Nasal Secretions in Humoral Immunodeficiencies. <i>Laryngoscope</i> , 2006, 116, 239-244.	2.0	7
71	Membrane Dynamics and Organization of the Phagocyte NADPH Oxidase in PLB-985 Cells. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 608600.	3.7	7
72	Antioxidative capacity in patients with common variable immunodeficiency. <i>Journal of Clinical Immunology</i> , 2000, 20, 221-226.	3.8	5

#	ARTICLE	IF	CITATIONS
73	Serum ECP levels and methacholine challenge in infants with recurrent wheezing. <i>Annals of Allergy, Asthma and Immunology</i> , 2002, 89, 498-502.	1.0	5
74	Signed outside: a surface marker system for transgenic cytoplasmic proteins. <i>Gene Therapy</i> , 2010, 17, 1193-1199.	4.5	5
75	Lentiviral gene therapy vector with UCOE stably restores function in iPSC-derived neutrophils of a CDG patient. <i>Matters</i> , 2018, 2018, .	1.0	5
76	Treatment of HCV infection with interferon alpha-2b and ribavirin in a patient with X-linked lymphoproliferative syndrome. <i>European Journal of Pediatrics</i> , 2006, 165, 348-350.	2.7	4
77	Reactive Oxygen Species Abrogate the Anticarcinogenic Effect of Eicosapentaenoic Acid in Atm-Deficient Mice. <i>Nutrition and Cancer</i> , 2010, 62, 584-592.	2.0	4
78	Newborn Screening for Primary Immunodeficiencies: Focus on Severe Combined Immunodeficiency (SCID) and Other Severe T-Cell Lymphopenias. <i>International Journal of Neonatal Screening</i> , 2015, 1, 89-100.	3.2	4
79	Novel Diagnostic Tool for p47 -Deficient Chronic Granulomatous Disease Patient and Carrier Detection. <i>Molecular Therapy - Methods and Clinical Development</i> , 2019, 13, 274-278.	4.1	3
80	Response: Protecting against Aspergillus infection in CGD. <i>Blood</i> , 2009, 114, 3498-3498.	1.4	2
81	Unusual dermatological presentation and immune phenotype in <scp>SCID</scp> due to an <i>IL7R</i> mutation: the value of whole-exome sequencing and the potential benefit of newborn screening. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, e147-e148.	2.4	2
82	Preliminary Evidence for a Compromised T-Cell Compartment in Maltreated Children with Depression and Posttraumatic Stress Disorder. <i>NeuroImmunoModulation</i> , 2015, 22, 303-310.	1.8	1
83	Gene Therapy for X-Linked Chronic Granulomatous Disease (Net4CGD). <i>Human Gene Therapy Clinical Development</i> , 2015, 26, 88-90.	3.1	1
84	S.7. IL-17 Signaling Defects in Patients with Candida Albicans and/or Staphylococcus Aureus Infections. <i>Clinical Immunology</i> , 2009, 131, S135.	3.2	0
85	Reply to Agger and Kowalski. <i>Clinical Infectious Diseases</i> , 2010, 50, 1325-1326.	5.8	0
86	Development of a pCCLChim Lentiviral Vector for Gene Therapy of Patients with Chronic Granulomatous Disease (CGD) due to p47-phox Deficiency. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 139, AB186.	2.9	0
87	Autophagy proteins stabilize pathogen-containing phagosomes for prolonged MHC II antigen processing. <i>Journal of Experimental Medicine</i> , 2013, 210, 210130IA64.	8.5	0